Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1
30/06/2026 13:41
BRIEF-Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1 June 30 (Reuters) - Design Therapeutics Inc DSGN.O:
DESIGN THERAPEUTICS ANNOUNCES INITIATION OF PATIENT DOSING IN PHASE 1 MULTIPLE ASCENDING DOSE TRIAL OF DT-818 FOR MYOTONIC DYSTROPHY TYPE-1
DESIGN THERAPEUTICS - EXPECTS PHASE 1 DT-818 DATA IN 2027
Source text: ID:nGNXbmdxL8
Further company coverage: DSGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1